Found 9 results
Author Title [ Type(Desc)] Year
Filters: Author is Alousi, Amin M  [Clear All Filters]
Journal Article
J. E. Levine, Logan, B. R., Wu, J., Alousi, A. M., Bolaños-Meade, J., Ferrara, J. L. M., Ho, V. T., Weisdorf, D. J., and Paczesny, S., Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study., Blood, vol. 119, no. 16, pp. 3854-60, 2012.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials., Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network., Blood, vol. 114, no. 3, pp. 511-7, 2009.
J. E. Levine, Logan, B., Wu, J., Alousi, A. M., Ho, V., Bolaños-Meade, J., and Weisdorf, D., Graft-versus-host disease treatment: predictors of survival., Biol Blood Marrow Transplant, vol. 16, no. 12, pp. 1693-9, 2010.
J. Bolaños-Meade, Wu, J., Logan, B. R., Levine, J. E., Ho, V. T., Alousi, A. M., Weisdorf, D. J., and Luznik, L., Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302., Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802., Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801., Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.